Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ropinirole: current status of the studies.

Literature DB >> 15675719

Ropinirole: current status of the studies.

Abstract

Ropinirole is a modern, non-ergoline dopamine agonist which has been shown to be effective as monotherapy as well as combination therapy against idiopathic Parkinson's disease. In addition to improving bradykinesia, rigor and tremor, it will ameliorate the abilities of daily living as well as depressive mood. The long-term complications of L-dopa are diminished and the existing complications are reduced. A neuroprotective effect is under discussion. In addition to Parkinson's disease, ropinirole is also used successfully in the treatment of restless legs syndrome.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2004 PMID： 15675719 DOI： 10.1007/s00415-004-1604-8

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

55 in total

1. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

Authors: A D Korczyn; E R Brunt; J P Larsen; Z Nagy; W H Poewe; S Ruggieri
Journal: Neurology Date: 1999-07-22 Impact factor: 9.910

2. Equivalent doses of ropinirole and bromocriptine.

Authors: W H Jost
Journal: Eur J Neurol Date: 1999-09 Impact factor: 6.089

3. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors: O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal: N Engl J Med Date: 2000-05-18 Impact factor: 91.245

4. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.

Authors: D C Rogers; B Costall; A M Domeney; P A Gerrard; M Greener; M E Kelly; J J Hagan; A J Hunter
Journal: Psychopharmacology (Berl) Date: 2000-07 Impact factor: 4.530

5. An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication.

Authors: M Canesi; A Antonini; C B Mariani; S Tesei; A L Zecchinelli; M Barichella; G Pezzoli
Journal: J Neural Transm (Vienna) Date: 1999 Impact factor: 3.575

6. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality.

Authors: B Saletu; G Gruber; M Saletu; N Brandstätter; C Hauer; W Prause; K Ritter; G Saletu-Zyhlarz
Journal: Neuropsychobiology Date: 2000 Impact factor: 2.328

Ropinirole: current status of the studies.

1. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

2. Equivalent doses of ropinirole and bromocriptine.

3. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

4. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.

5. An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication.

6. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality.

7. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?

Review 8. Ropinirole: a review of its use in the management of Parkinson's disease.

9. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.

10. Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease.

1. Ropinirole in restless legs syndrome and periodic limb movement disorder.

2. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells.

3. Can ropinirole modulate reinforcing subjective effects of cocaine in humans?